Solifenacin induced dyskinesia

Aşırı aktif mesane inkontinans olsun ya da olmasın urgency ile ilişkili kronik bir durumdur. Solifenazin günde tek doz kullanılan selektif antimuskarinik bir ajandır. Günde 5mg olarak başlanır, tolere edilebilirse 10 mg’a artırılabilir. Biz burada solifenazin kullanımı sonrası ortaya çıkan ve ilacın kesilmesini takiben birkaç gün içinde ortadan kaybolan diskinezili bir olguyu sunduk.

Solifenazin’e bağlı diskinezi

Overactive bladder syndrome is a chronic condition characterised by urgency, with or without associated urge incontinence. Solifenacin succinate is a once daily, bladderselective antimuscarinic available. The recommendeddose is 5 mg once daily and can be increased to 10 mgonce daily if 5 mg is well tolerated. We report here a casewith dyskinesia emerged following the use of solifenacin,and disappeared in a few days with stopping the agent.

PDF

___

1. Wagg A, Wyndaele JJ, Sieber P. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis. Am J Geriatr Pharmacother 2006;4(1):14-24.
2. Chancellor MB, Zinner N, Whitmore K, et al. Efficacy of solifenacin in patients previously treated with tolterodine extended release
4 mg: results of a 12-week, multicenter, open-label, flexible-dose study. Clin Ther 2008;30(10):1766-81.
3. Basra R, Kelleher C. A review of solifenacin in the treatment of urinary incontinence. Ther Clin Risk Manag. 2008;4(1):117-28.
4. Cardozo L, Lisec M, Millard R, et al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 2004;172(5):1919-24.
5. Suzuki M, Noguchi Y, Okutsu H, Ohtake A, Sasamata M. Effect of antimuscarinic drugs used for overactive bladder on learning in a rat passive avoidance response test. Eur J Pharmacol 2007;557(2-3):154-8.
6. Piecoro LT, Wermeling DP, Schmitt FA, Ashford JW. Seizures in patients receiving concomitant antimus- carinics and acetylcholinesterase inhibitor. Pharmacotherapy 1998;18(5):1129-32.